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Stenotic neointimal hyperplasia is a significant
clinical complication that limits the usefulness of vas-
cular reconstructive procedures, including balloon
angioplasty, endarterectomy, stenting, and the inser-
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Purpose: Recently, we designed and characterized a novel expanded polytetrafluoroethyl-
ene (ePTFE)–based local drug delivery approach that selectively concentrates infused
pharmacologic agents specifically within those blood layers adjacent to the graft wall and
at downstream anastomotic sites. In this study, we locally administrated standard
heparin therapy and evaluated its effects on neointimal hyperplasia formation in a
baboon model of aortoiliac bypass graft placement.
Methods: Six adult male baboons underwent bilateral aortoiliac bypass grafting with
ringed ePTFE (4 mm internal diameter × 5 cm length). In each animal, the distal anas-
tomosis of one graft was continuously infused with heparin (50 U/h) and the distal
anastomosis of the contralateral graft was infused with saline solution at the same rate
(2.5 µL/h), with osmotic pumps implanted for 4 weeks. Platelet counts and activated
partial thromboplastin time measurements were performed weekly. The specimens were
harvested at 4 weeks and were subjected to morphometric analysis. Cell proliferation
was assessed with bromodeoxyuridine immunostaining.
Results: All the harvested grafts were patent except for one control graft. There were no
significant differences in platelet counts or activated partial thromboplastin time measure-
ments taken before and during heparin infusion. As expected, there were no significant dif-
ferences in graft neointimal hyperplasia and cell proliferation at the proximal anastomoses
between the heparin-infused and control grafts. In contrast, at the treated distal anasto-
moses, heparin infusion significantly reduced the graft neointimal area by 65% and the cell
proliferation index by 47% as compared with the untreated control distal anastomoses.
Conclusion: These results show that local infusion of heparin significantly reduces distal
anastomotic neointimal hyperplasia and cell proliferation without measurable systemic
anticoagulation or other side effects. Thus, this approach may represent an attractive
strategy for prolonging ePTFE bypass graft patency. (J Vasc Surg 2000;31:354-63.)
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tion of prosthetic vascular grafts. After percutaneous
transluminal coronary angioplasty, restenosis rates of
25% to 50% have been reported within 3 weeks to 6
months.1,2 Restenosis after carotid endarterectomy
develops in 10% to 30% of patients during the first
year.3,4 The incidence rate of stenosis in the first
postoperative year varies from 20% to 30% in
femorodistal bypass graft recipients and from about
50% to 60% in patients with hemodialysis access
grafts.5-7 In response to vascular injury, neointimal
hyperplasia develops as a consequence of smooth
muscle cell (SMC) proliferation, migration, and the
subsequent synthesis by SMC of extracellular matrix
proteins. Thus, the targeting of SMC functions is
considered a promising strategy for the control of
neointimal hyperplasia.
Heparin is a mucopolysaccharide found in most
tissues. Heparin inhibits thrombin and activated fac-
tors IX, X, XI, and XII, which are involved in the con-
version of prothrombin to thrombin, thereby reduc-
ing thrombin formation. Consequently, heparin may
significantly prolong whole blood and plasma clotting
times. In addition, heparin has a potent antiprolifera-
tive effect on vascular SMCs, and this effect is inde-
pendent of its anticoagulant activity8 and involves a
specific blocking step during the S phase of the cell
cycle.9 In models of endothelial denudation in the rat,
sustained heparin infusions were shown to decrease
neointimal thickening by 40% to 50%.8,10-12 In the
same model, a single heparin bolus before angioplas-
ty produced a 55% decrease in early medial cell prolif-
eration.13 On the basis of such animal studies, the use
of heparin and its low–molecular weight derivatives
have been tested for the prevention of restenosis in
several clinical trials.14-18 Unfortunately, none of
these trials showed the ability of systemic heparin to
reduce restenosis. Geary et al19 have reported that
low–molecular weight heparin was also ineffective for
the inhibition of SMC proliferation and neointimal
hyperplasia in a baboon model of arterial balloon
angioplasty. However, in another study, higher doses
of low–molecular weight heparin have been reported
to inhibit neointimal hyperplasia after balloon angio-
plasty in the baboon.20 In general, inadequate sys-
temic heparin levels may account for the failure of
heparin therapy in human and primate trials versus
studies in smaller animals and for the discordant
results obtained in similar baboon models,19,20
although other factors may play a role as well. Thus,
local heparin delivery approaches, which increase tar-
get site heparin levels while avoiding or minimizing
systemic side effects, could represent an attractive
alternative to systemic therapy. Recently, we designed
and characterized an expanded polytetrafluoroethyl-
ene (ePTFE)–based local drug delivery device that
selectively concentrates infused pharmacologic agents
specifically within those blood layers (boundary lay-
ers) adjacent to the graft wall and at downstream
anastomotic sites. This approach for the local infusion
of heparin has been successfully used in both rabbit
and dog models of vein replacement and produced a
marked increase in graft patency with a significant
reduction of neointimal hyperplasia without systemic
anticoagulation.21,22 To further evaluate the efficacy
of this approach in a primate arterial graft model, we
determined whether local infusion of heparin could
inhibit anastomotic neointimal hyperplasia and cell
proliferation in baboons after aortoiliac bypass graft-
ing with small-caliber ePTFE grafts. This study was
also designed to evaluate the feasibility of this local
drug delivery approach for applications in humans.
MATERIALS AND METHODS
Local infusion device. The local infusion device
was constructed from a ringed ePTFE (30-µ) clinical
vascular graft (Gore-Tex, WL Gore and Associates,
Inc, Flagstaff, Ariz) as previously described.21-23
Briefly, ringed ePTFE (thin wall, 4 mm internal diam-
eter, 5 cm in length) was encased in 5 mm–long sili-
cone rubber (Silastic, Dow Corning, Midland, Mich)
to form a cuff reservoir, which was made adjacent to
one end of a segment of ePTFE graft. An implantable
osmotic pump (model 2ML4, Alza Co, Palo Alto,
Calif) was connected to the tubing of the reservoir
and delivered heparin directly through the graft wall
in the region adjacent to the distal anastomosis, there-
by achieving a high drug concentration downstream
along the graft-blood interface. These osmotic pumps
delivered at a predictable rate of 2.5 µL/h during a
period of 28 days. The pumps for treated grafts were
loaded with 2 mL of heparin (20,000 U/mL from
porcine intestinal mucosa) in sterile water as provided
by the manufacturer (Wyeth Laboratories Inc,
Philadelphia, Pa), whereas the pumps used in the con-
trol studies were loaded with 2 mL of phosphate-
buffered saline solution (PBS). The treated grafts
received a local infusion of heparin for 28 days at the
rate of 50 U/h, which was equivalent to an average
rate of 4 to 5 U/kg/h. Satisfactory drug delivery was
confirmed at the time of harvest with observations
that all tubings were patent and that all pumps con-
tained a residual volume of approximately 0.3 mL of
heparin or saline solution.
Computational modeling of local heparin
concentrations. Briefly, the agents infused with this
method enter the bloodstream in a circumferentially
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uniform manner at the interface between the flow-
ing blood and the ePTFE graft wall. The infusate
then is carried downstream in an annular configura-
tion, maintaining high concentrations along the
graft wall locally while minimizing total volume
delivery and systemic load. To model the heparin
concentrations and velocity flow fields under steady
flow, the computational code, FLUENT/UNS,
was used (Lebanon, NH). The domain was divided
into finite control volumes with an axisymmetric
Cartesian grid to numerically solve the governing
equations. Fine grid spacing was used near the walls
because of the thin concentration boundary layer
that developed, particularly under conditions of low
particle diffusivity. The governing differential equa-
tions were approximated by a set of algebraic equa-
tions that were evaluated at each grid node. Grid
generation and model verification were performed
according to standardized techniques. This compu-
tational approach has been used to calculate the con-
centrations of heparin and various other infused
materials, as described previously.23
Animal model. Six male baboons (Papio cyno-
cephalus) aged 2 to 3 years and weighing 10 to 13 kg
(11.8 ± 0.9 kg) received bilateral aortoiliac grafts.
This model has been previously described.24-27
Briefly, after an abdominal midline incision, ePTFE-
based local infusion devices (4.0 mm internal diame-
ter, 5 cm length; silicone cuff reservoir encased at one
end) were placed bilaterally between the distal aorta
and the common iliac artery with end-to-side anasto-
moses and continuous 7-0 polypropylene sutures.
After the isolation of the aorta and the iliac arteries, all
the animals underwent bolus intraoperative heparin
therapy (100 U/kg). Neither aspirin nor any other
agents were given before or during the procedure. All
anastomoses were standardized with respect to graft
diameter, suture size, and animal size, and all anasto-
moses were constructed by one surgeon (C.C.). The
cuff reservoir was positioned approximately 1 cm
proximal to the distal anastomosis. On completion of
the anastomoses, an osmotic pump preloaded with
heparin was connected to the infusion cuff reservoir
on one side and another osmotic pump that was pre-
loaded with PBS was connected to the infusion cuff
reservoir on the contralateral side as a control. The
side of placement of heparin-infused grafts versus
saline solution–infused grafts was randomized. These
pumps were implanted in the abdominal cavity (Fig
1). The incisions were closed with a 3-0 polyglactin
suture. The blood samples that were drawn before
surgery, at days 1, 8, 14, 21, and 28, were analyzed
for hematologic parameters, including platelet count,
hematocrit, white blood cell count, and activated par-
tial thromboplastin time. Bromodeoxyuridine (BrdU;
Sigma Chemical Co, St Louis, Mo), 50 mg/kg dis-
solved in 50 mL of normal saline solution, was admin-
istered subcutanously 24 hours before death at 28
days. Grafts, and adjacent 3-cm segments of attached
vessel at each anastomosis, were harvested and fixed in
10% buffered formalin (Baxter Diagnostics Inc,
McGaw Park, Ill). All the animal procedures were
approved by the Institutional Animal Care and Use
Committee and were conducted in accordance with
federal guidelines (Guide for the Care and Use of
Laboratory Animals, National Institutes of Health
Publication No. 86-23, 1985) and with the animal
welfare act and applicable University policies.
Histology and morphometry. After fixation,
the grafts were embedded in paraffin and sectioned at
the midpoint between the heel and toe of each anas-
tomosis at a distance of 1 to 2 mm from the heel of
each anastomosis and at 5-mm intervals along the
entire graft length. Five-micron sections were cut and
stained with hematoxylin and eosin and with
Verhoeff-Masson stain. Cell ingrowth overlying the
Fig 1. Configuration of implanted expanded polytetrafluo-
roethylene–based local infusion devices. In each animal,
expanded polytetrafluoroethylene–based local infusion
devices were placed bilaterally between the distal aorta and
common iliac arteries with end-to-side anastomoses.
Infusion cuff reservoirs were positioned close to the distal
anastomoses of each graft. One graft received local heparin
infusion via an implanted osmotic pump, and the contralat-
eral graft was identically infused with phosphate-buffered
saline solution only, thereby serving as a paired internal con-
trol. All grafts were infused for 28 days before harvesting.
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luminal surface of the graft adjacent to the anasto-
mosis was considered to be graft neointima. Cell pro-
liferative tissue overlying the internal elastic lamina of
native vessels was considered to be vessel neointima.
Morphometric measurements of the area of anasto-
motic neointima were performed with computer
image analysis software (Optimas, Bioscan, Inc,
Edmonds, Wash) on a magnified image relayed from
a microscope-mounted video camera to a digitizing
pad and video monitor (Thomas Optical, Columbus,
Ga) as previously described.28,29 The morphometric
results represent an average of two tissue sections
taken midway between the heel and the toe of each
anastomosis. All the tissues were analyzed in a blind-
ed manner with respect to whether they were derived
from treated or control grafts.
Immunocytochemistry. The avidin-biotin com-
plex immunoperoxidase procedure (LSAB Kit, Dako
Co, Carpenteria, Calif) was used to identify determi-
nants characterizing neointimal cell types and prolif-
erating cells as previously described.30,31 Briefly,
immunostaining for α-actin and factor VIII–related
antigen was performed to identify SMCs and
endothelial cells, respectively. Proliferating cells were
identified with anti-BrdU monoclonal antibody
(Dako Co). BrdU-positive cells were quantified man-
ually with a cell-counting technique on a calibrated
micrometer grid with microscopy (×400). In each
field, all the cells were counted and the number of
positively stained cells was expressed as a percentage
of total cells to arrive at the BrdU index. A minimum
of 10 fields was quantified per section.
Fig 2. Neointimal hyperplasia at distal anastomoses. Verhoeff-Masson stain. Collagens are
blue, elastin is black, and other elements are red. A, Distal anastomosis infused with phosphate-
buffered saline solution (control). B, Distal anastomosis infused with heparin. L, Lumen; N,
neointima. (Original magnification, ×40).
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Statistical analysis. Statistical analysis was per-
formed on a Macintosh Quadra 650 computer with
use of Excel 4.0 statistical software (Microsoft Corp,
Redmond, Wash). Comparisons of neointimal areas
and cell proliferation between the heparin-treated
grafts and the control grafts were made with the
Student t test (two-tailed) for paired data.
Comparisons of hematologic measurements at dif-
ferent time points were made with analysis of vari-
ance. The values are given as the mean ± the stan-
dard error. The results were considered significant if
the P value was less than .05.
RESULTS
Anastomotic neointimal hyperplasia. All of
the study animals survived uneventfully and without
evidence of clinical side effects. All of the aortoiliac
grafts were patent at tissue harvesting except for one
control graft that was occluded. Measurable neointi-
mal hyperplasia had developed at both proximal and
distal anastomoses of the grafts in the control and
the heparin-treated groups. SMCs were the major
type of anastomotic neointimal cells identified by α-
actin immunostaining. Endothelial cells covered the
surfaces of all of the anastomotic neointimas as
shown with factor VIII–related antigen immuno-
staining. The distal anastomosis of the graft on one
side received heparin, and the distal anastomosis on
the contralateral side received PBS as a paired con-
trol. At the treated distal anastomoses, local heparin
infusion significantly reduced graft neointimal area
and vessel neointimal area by 65% and 58%, respec-
tively (Table I), as compared with measurements
taken at the distal anastomoses of the control grafts
(Fig 2). In the comparison of distal and proximal
anastomoses, graft neointima and vessel neointima
at distal anastomoses were also significantly reduced
by 71% and 44%, respectively, versus the proximal
anastomoses of the heparin-infused grafts. However,
no differences were seen in the proximal versus dis-
tal anastomoses for the PBS-infused grafts (Table I).
Thus, with the attachment of the infusion device at
a position in proximity to the distal anastomosis,
heparin treated only the distal anastomosis and sig-
nificantly reduced neointimal hyperplasia only at
that site.
Neointimal cell proliferation. Cell prolifera-
tion was assayed with BrdU labeling. There was no
significant difference in the neointimal cell prolifer-
ation index at the proximal anastomoses of the
treated and the control grafts (Table II). In con-
trast, heparin infusion significantly reduced neointi-
mal cell proliferation by 47% at the distal anasto-
moses of the heparin-treated grafts as compared
with the distal anastomoses of the control grafts
(Table II; Fig 3). Furthermore, similar cell prolifer-
ation rates were seen at the proximal and distal
anastomoses of the control grafts (P > .05).
However, local heparin infusion significantly
reduced cell proliferation at the distal anastomoses
of the treated grafts by 54% versus the proximal
anastomoses of the same heparin-infused grafts.
Thus, local infusion of heparin significantly reduced
neointimal cell proliferation at the distal graft anas-
tomoses.
Hematologic assays. The study animals showed
no weight loss during the experimental period (data
not shown). Platelet counts, hematocrits, total leuko-
cyte counts, and activated partial thromboplastin
times were all within normal ranges at the time of
death (Table III). Thus, the local infusion of heparin
was without measurable systemic effects.
Table I. Effect of local infusion of heparin on neointimal areas at the anastomoses of aortoiliac artery
bypass grafts in baboons
Control (mm2) Treated* (mm2) P value†
Proximal anastomosis
Graft neointima (n = 5) 0.56 ± 0.13 0.80 ± 0.19 .17
Vessel neointima (n = 5) 0.47 ± 0.11 0.41 ± 0.10 .43
Distal anastomosis
Graft neointima (n = 5) 0.65 ± 0.12 0.23 ± 0.11 .005 (65% reduction)
Vessel neointima (n = 5) 0.53 ± 0.17 0.22 ± 0.12 .034 (58% reduction)
P value‡
For graft neointima .45 .01 (71% reduction)
For vessel neointima .59 .04 (44% reduction)
*In each animal, the distal anastomosis of the graft on one side received heparin (treated) and the distal anastomosis on the contralat-
eral side received phosphate-buffered saline solution only (control). 
†P value determined with Student t test.
‡Comparison of proximal versus distal anastomoses.
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DISCUSSION
Neointimal hyperplasia is a complicated cellular
and molecular response to mechanical vascular
injury. In general, this response is characterized by
SMC proliferation, migration, and extracellular
matrix production, with the final result being vessel
wall thickening and luminal narrowing. Much of our
understanding of neointimal hyperplasia has been
gained from studies performed in animal models
involving balloon-catheter de-endothelialization,
balloon-catheter angioplasty, surgical endarterecto-
my, and the implantation of vein grafts or synthetic
graft materials. The model of balloon injury of the
rat or rabbit common carotid artery has been stud-
ied extensively. However, large animal models with
pigs, dogs, or primates may be more relevant to clin-
ical neointimal hyperplasia because the vessel archi-
tecture and hemodynamics in larger animals more
closely resemble those of humans. In this study, we
used baboons because these primates also exhibit a
high degree of genetic similarity with humans. The
baboon model of bilateral aortoiliac ePTFE bypass
grafting has also been well characterized by our
group and other investigators.24-27 In this model, a
significant amount of neointimal tissue usually
develops at graft anastomoses within several weeks
after graft implantation. Small-caliber ePTFE grafts
were used, which directly addresses clinically rele-
vant applications.
In humans, ePTFE grafts have functioned reason-
Fig 3. Cell proliferation in anstomotic intimal lesions. Immunoperoxidase staining of bro-
modeoxyuridine-labeled cells. Dark brown color represents positive staining results. A, Distal
anastomosis infused with phosphate-buffered saline solution (control). B, Distal anastomosis
infused with heparin. L, Lumen. (Original magnification ×400).
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ably well in large and medium-sized arteries but have
had limited success for vessel diameters of less than 6
mm because of early graft occlusion. The primary
patency rates at 4 years for ePTFE infrapopliteal
grafts32,33 and aorta-coronary grafts34 are only 12%
and 14%, respectively. Anastomotic neointimal hyper-
plasia has been shown to be most pronounced at the
downstream anastomosis35,36 and may develop in part
as a consequence of factors related to compliance mis-
match, endothelial dysfunction, ongoing platelet
deposition, monocyte recruitment, and chronic
inflammatory reactions. Growth factors, such as
platelet-derived growth factor and basic fibroblast
growth factor (bFGF), which may be derived from
platelets, endothelial cells, SMCs, and monocytes/
macrophages, may stimulate fibroblast and SMC pro-
liferation in the developing stenotic lesion.37,38 Thus,
new strategies that target these pathways may eventu-
ally prolong patency rates for small-caliber ePTFE
grafts in humans.
In this context, conventional heparin preparations
are also of interest because heparin has been shown to
inhibit baboon, human, bovine, and rat SMC prolif-
eration in culture8,39-41 and because heparin is effec-
tive for limiting neointimal hyperplasia after experi-
mental arterial injury in some models.10 Even when
its anticoagulant activity is diminished, heparin
potently inhibits the vascular response to injury.8
Heparin infusion inhibits SMC proliferation in tissue
culture by inhibiting DNA synthesis and by limiting
the transcription of genes necessary for cell passage
from G0 through G1 and into the S phase.42-44 These
results suggest that heparin should be effective at
inhibiting restenosis in humans, but the clinical trial
results of heparin in coronary balloon angioplasty
have been negative.14,16,45 Furthermore, the systemic
administration of heparin failed to inhibit neointimal
hyperplasia in a baboon angioplasty model even
though the dose of heparin used in that study was
previously shown to inhibit serum-induced baboon
SMC proliferation in culture39 and to effectively
inhibit SMC proliferation and neointimal thickening
after carotid artery injury in the rat.46 Several factors
may have contributed to these observed differences in
heparin effects, including variations in the heparin
preparation, differences in the route, dose, and dura-
tion of heparin administration, differences in the
degree of arterial injury in the various models, and
interspecies differences in SMC growth control. In
humans and primates, therapeutic heparin levels for
inhibition of SMC may be quantiatively increased ver-
sus heparin requirements in lower animals. Thus, a
high dose of systemic low–molecular weight heparin
was effective for reducing neointimal hyperplasia in
baboons, although at the dose used, hemostasis was
significantly impaired.20
Table II. Effect of local heparin infusion on neointimal cell proliferation at the anastomoses of aortoiliac
artery bypass grafts in baboons
Control graft Treated graft P value†
Proximal anastomosis (n = 5) 8.48% ± 2.22% 9.07% ± 2.09% .59
Distal anastomosis (n = 5) 7.81% ± 0.63% 4.13% ± 1.15% <.001 (47% reduction)
P value .64 .002 (54% reduction)
*Comparison of proximal versus distal anastomoses.
†P value determined with Student t test.
Table III. Hematologic assessments of experimental baboons with aortoiliac bypass grafts and local infu-
sion of heparin*
Before surgery Day 1 Day 8 Day 14 Day 21 Day 28 P value†
Platelet 370 ± 105 407 ± 86 377 ± 69 379 ± 58 365 ± 39 406 ± 57 .98
HCT 36.20 ± 1.91 38.47 ± 0.59 39.33 ± 0.19 36.67 ± 1.67 36.40 ± 2.34 39.23 ± 1.91 .23
WBC 7.07 ± 2.12 11.33 ± 3.39 11.83 ± 5.08 11.07 ± 3.15 12.03 ± 4.86 9.83 ± 2.29 .76
aPTT 29.65 ± 2.08 31.07 ± 2.25 28.65 ± 2.14 32.07 ± 2.91 31.40 ± 2.50 29.43 ± 2.88 .24
HCT, Hematocrit (%); WBC, white blood cell count (cells/µL × 10–3); aPTT, activated partial thromboplastin time (seconds).
*In each animal, one aortoiliac graft received local infusion of heparin for 28 days at the rate of 50 U/h, which was equivalent to an
average rate of 4 to 5 U/kg/h, and the contralateral graft received local infusion of the equivalent volume of phosphate-buffered saline
solution. Platelet counts were determined as platelets/µL × 10–3.
†P value determined with analysis of variance.
Because high-dose systemic therapies may pose
unacceptable risks, recent interest has focused on
local drug administration approaches that have the
potential to maximize local drug concentrations
while minimizing systemic drug levels and side
effects. Edelman et al47 showed that controlled
adventitial delivery of heparin could markedly
reduce SMC proliferation in the rat model. Recently,
we have characterized a PTFE-based local drug
deliver device that has been used with infused
heparin to improve synthetic vein graft patency in
rabbits and dogs.21-23 In the present study, heparin
was continuously delivered (via an implanted osmot-
ic pump) to the distal anastomoses of aortoiliac
PTFE grafts in baboons, and contralateral grafts in
the same animals were infused with PBS only. After
28 days, the local infusion of heparin significantly
reduced neointimal areas at treated anastomoses by
58% to 65% as compared with the controls. Local
heparin therapy also significantly reduced neointimal
cell proliferation at treated anastomoses by an aver-
age of 47%. These findings, concordant with our
previous observations in rabbit and dog models,21,22
represent the first reported results in primates docu-
menting inhibition with soluble heparin infusion of
ePTFE graft intimal hyperplasia.
The local infusion devices were constructed with
standard clinical ePTFE grafts (30 µ internodal dis-
tance), which are almost impervious to the extravasa-
tion of blood elements as a result of their hydropho-
bic nature and small pore size. However, agents exter-
nal to the graft can be infused through the graft wall
into the blood stream with implantable osmotic
minipumps, as in the present study. This approach has
also been successfully used in animal studies to deliv-
er into implanted ePTFE grafts other agents, includ-
ing bFGF,30 mitotoxin,28 and nitric oxide donors.31
The approach has also been characterized by compu-
tational fluid dynamics, flow visualization techniques,
and local sampling downstream of infusion sites.23
These studies have shown that drug mass transport is
predominately mediated by convective (vs diffusive)
mechanisms. Thus, the typically high concentrations
of infused agents can usually be maintained for sever-
al centimeters along the downstream graft wall and at
the distal graft anastomosis.23 On the basis of compu-
tational modeling, the anastomotic wall heparin con-
centrations in the present study are estimated to have
been at least 4 U/mL and systemic heparin levels
were no more than one tenth this value.23 Thus, the
local drug delivery approach is advantageous because
it is possible to achieve high local concentrations of
agents at vascular wall sites where treatment is needed
while reducing the side effects of systemic drug deliv-
ery, such as the risk of hemorrhage. The method also
has the following advantages: (1) agents may be
administered over extended periods of time; (2) aver-
age local drug concentrations are nearly constant over
time; (3) local drug concentrations can be calculated
to reasonable approximation a priori; (4) small quan-
tities of toxic drugs may be delivered safely (ie, with-
out systemic effects); and (5) overall drug usage and
cost of treatment may be reduced.
The mechanisms whereby heparin inhibits SMC
hyperplasia are under active investigation. For exam-
ple, heparin’s growth inhibitory effects might in
part be mediated through inhibition of second mes-
senger pathways leading to proto-oncogene expres-
sion important for cell cycling.44,48 Heparin can
inhibit intracellular kinases involved in signal trans-
duction49 and may be involved in the regulation of
transcription activator proteins.50 Heparin is able to
modulate the functions and expression of several
growth factors (eg, heparin binds platelet-derived
growth factor A chain and inhibits its mitogenic
activity).41 Heparin also inhibits bFGF-stimulated
growth responses of endothelial and SMCs13,51 and
is able to deplete the amount of bFGF present in the
wall of injured vessels.13 Furthermore, heparin
inhibits epidermal growth factor receptor expres-
sion.52 In contrast, heparin potentiates the inhibito-
ry effects of transforming growth factor–β by releas-
ing it from a carrier protein.53 Heparin selectively
inhibits the production of specific proteases impor-
tant for degrading extracellular matrix, a critical
process for cell movement and proliferation. These
proteases include tissue-type plasminogen activator,
interstitial collagenase, stromelysin, and a 92-kd
gelatinase.39,46,54,55 Taken together, heparin may
potentially play a role in multiple complex biochem-
ical and cellular events involved in processes of SMC
migration and proliferation.
In summary, the local infusion of heparin effec-
tively inhibited SMC proliferation and neointimal
hyperplasia at the distal anastomoses of aortoiliac
PTFE bypass grafts in baboons after 4 weeks
implantation without producing measurable sys-
temic anticoagulation. These findings document
that local continuous heparin in sufficient concen-
tration can reduce ePTFE graft intimal hyperplasia
in baboons and suggest that the approach may be
safe and effective for preserving ePTFE graft paten-
cy in humans.
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